Loading...
Market
Story
Eli Lilly's Tirzepatide Zepbound Cuts Diabetes Risk by 94%, Achieves 23% Weight Loss
Aug 20, 2024, 11:00 AM
Eli Lilly's weight loss drug, Zepbound, featuring tirzepatide, has demonstrated significant efficacy in reducing the risk of developing type 2 diabetes. In a long-term study, the drug reduced the risk by 94% in adults with pre-diabetes and obesity or overweight, compared to a placebo. The three-year SURMOUNT-1 trial also showed that patients on the highest dose of Zepbound lost an average of 23% of their body weight over 176 weeks. These findings bolster the case for the drug's long-term use in managing obesity and preventing diabetes. The study's results have positively impacted Eli Lilly's stock performance, with shares seeing a pre-market increase.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Yes • 50%
No • 50%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Yes • 50%
No • 50%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Not in Top 50 • 25%